1. Market Research
  2. > Klebsiella Infections - Pipeline Review, H2 2013

Klebsiella Infections - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 48 pages

Klebsiella Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Klebsiella Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Klebsiella Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Klebsiella Infections. Klebsiella Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Klebsiella Infections.
- A review of the Klebsiella Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Klebsiella Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Klebsiella Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Klebsiella Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Klebsiella Infections - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Klebsiella Infections Overview 6
Therapeutics Development 7
Pipeline Products for Klebsiella Infections - Overview 7
Pipeline Products for Klebsiella Infections - Comparative Analysis 8
Klebsiella Infections - Therapeutics under Development by Companies 9
Klebsiella Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Klebsiella Infections - Products under Development by Companies 14
Klebsiella Infections - Companies Involved in Therapeutics Development 15
The Medicines Company 15
Omnia Molecular Ltd. 16
Northern Antibiotics Oy 17
Nosopharm SAS 18
Sealife PHARMA GMBH 19
Indel Therapeutics Inc. 20
Abgentis Limited 21
Klebsiella Infections - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Assessment by Therapeutic Class 31
Drug Profiles 33
(biapenem + RPX-7009) - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
NOSO-95 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
NAB-741 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
NAB-7061 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
SLP-0907 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Gram Negative Antibacterial Programs - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Compound-1 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Eskape Bacteria Project - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Klebsiella Infections - Recent Pipeline Updates 44
Klebsiella Infections - Product Development Milestones 45
Featured News and Press Releases 45
Jan 06, 2011: NovaBay Reports Activity Of NVC-422 Against Deadly Superbug Producing NDM-1 45
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48



List of Tables

Number of Products under Development for Klebsiella Infections, H2 2013 7
Number of Products under Development for Klebsiella Infections - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Comparative Analysis by Unknown Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Klebsiella Infections - Pipeline by The Medicines Company, H2 2013 15
Klebsiella Infections - Pipeline by Omnia Molecular Ltd., H2 2013 16
Klebsiella Infections - Pipeline by Northern Antibiotics Oy, H2 2013 17
Klebsiella Infections - Pipeline by Nosopharm SAS, H2 2013 18
Klebsiella Infections - Pipeline by Sealife PHARMA GMBH, H2 2013 19
Klebsiella Infections - Pipeline by Indel Therapeutics Inc., H2 2013 20
Klebsiella Infections - Pipeline by Abgentis Limited, H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Combination Products, H2 2013 23
Number of Products by Stage and Target, H2 2013 25
Number of Products by Stage and Mechanism of Action, H2 2013 27
Number of Products by Stage and Route of Administration, H2 2013 29
Number of Products by Stage and Molecule Type, H2 2013 30
Number of Products by Stage and Therapeutic Class, H2 2013 32
Klebsiella Infections Therapeutics - Recent Pipeline Updates, H2 2013 44



List of Figures

Number of Products under Development for Klebsiella Infections, H2 2013 7
Number of Products under Development for Klebsiella Infections - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 22
Number of Products by Top 10 Target, H2 2013 24
Number of Products by Stage and Top 10 Target, H2 2013 25
Number of Products by Top 10 Mechanism of Action, H2 2013 26
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 27
Number of Products by Top 10 Route of Administration, H2 2013 28
Number of Products by Stage and Top 10 Route of Administration, H2 2013 29
Number of Products by Stage and Top 10 Molecule Type, H2 2013 30
Number of Products by Top 10 Therapeutic Class, H2 2013 31
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 32



Companies Mentioned

The Medicines Company
Omnia Molecular Ltd.
Northern Antibiotics Oy
Nosopharm SAS
Sealife PHARMA GMBH
Indel Therapeutics Inc.
Abgentis Limited

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.